Preferred Label : Autologous Total Tumor mRNA and CMV-pp65-flLAMP mRNA Loaded Liposome Vaccine;
NCIt synonyms : Autologous Total Tumor mRNA/CMV-pp65-flLAMP mRNA-LPs; Autologous Total Tumor mRNA and CMV-pp65-flLAMP mRNA Loaded Lipid Particles; Autologous Total Tumor mRNA/CMV-pp65-flLAMP mRNA-loaded DOTAP Liposome Vaccine;
NCIt definition : An mRNA-based, personalized cancer vaccine consisting of total tumor RNA (TTRNA) derived
and amplified from autologous tumor cells and mRNA encoding the human cytomegalovirus
(CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein
with the full-length lysosome-associated membrane protein (flLAMP), formulated in
DOTAP lipid particles, with potential immunostimulatory and antineoplastic activities.
Upon administration of the autologous total tumor mRNA and CMV-pp65-flLAMP mRNA loaded
liposome vaccine, the mRNA is taken up, translated and presented by antigen presenting
cells (APCs). This leads to an induction of both cytotoxic T-lymphocyte and memory
T-cell dependent immune responses that specifically target and destroy the patient's
cancer cells that express these tumor antigens. The incorporation of flLAMP may route
CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class
II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV
pp65 protein is the primary component of the enveloped subviral particle of CMV and
is expressed in certain tumor types.;
NCI Metathesaurus CUI : CL1648134;
Origin ID : C178432;
UMLS CUI : C5555027;
Semantic type(s)
- concept_is_in_subset
- has_target
